WALTHAM, Mass., March 30, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that the audit report on its financial statements for the fiscal year ended December 31, 2008, included in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 30, 2009, contains a going concern qualification from its independent registered public accounting firm, Ernst & Young LLP.
